ROSE Diagnostics

ROSE Diagnostics

ROSE Diagnostics, with a valuation of $15 million, is raising funds on StartEngine. The company is revolutionizing cancer biopsies with point-of-care solutions that provide biopsy sample verification in five minutes. ROSE Diagnostics aims to reduce cancer patients’ stress, time to diagnosis, and cost by providing pathology review at the place and time of cancer biopsy procedures. The company has developed the product, run over 3,000 lab tests, and had a positive FDA pre-submission, and is set for clinical study in Q1 2025 with FDA submission planned for Q3 2025. Andrew Morris, Eric Brouwer, Donna Padavan, and Adolfo Velasquez founded ROSE Diagnostics in July 2023. The current crowdfunding campaign has a minimum target of $123,983.16 and a maximum target of $1.23 million. The campaign proceeds will be used for product development, company management, pre-clinical studies, clinical studies, and other corporate overheads.

Expand

Investment Overview

Raised this Round: Raised: $72,712

Deal Terms

Total Commitments ($USD)

Platform
StartEngine
Start Date
11/18/2024
Close Date
02/13/2025
Min. Goal
$123,983
Max. Goal
$1,234,986
Min. Investment

$490

Security Type

Equity - Common

Series

Series A

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$28.84

Pre-Money Valuation

$14,998,357

Company & Team

Company

Year Founded
2023
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Distribution Model
B2B2C
Margin
Medium
Capital Intensity
Low
Location
Carlsbad, California
Business Type
Growth
Company Website
Visit Website

Team

Employees
4
Prior Founder Exits?
No
Founder Name
Andrew Morris
Title
Board Member, Chief Executive Officer, Principal Accounting Officer
Founder Name
Adolfo Velazquez
Title
Board Member and Chief Technical Officer
Founder Name
Eric Brouwer
Title
Board Member, Chief Scientific Officer
Founder Name
Donna Padavan
Title
Board Member and VP of Clinical & Regulatory Affairs

Financials

as of October 31, 2024
 Revenue
$0
 Monthly Burn
$62,000
 Runway
10 months

Summary Profit and Loss Statement

FY 2023 FY 2022

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-63,761

$0

Summary Balance Sheet

FY 2023 FY 2022

Cash

$5,792

$0

Accounts Receivable

$0

$0

Total Assets

$5,792

$0

Short-Term Debt

$0

$0

Long-Term Debt

$0

$0

Total Liabilities

$0

$0

Create a free account today to gain access to Kingscrowd analytics and financials.

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Company Funding & Growth

Funding history

Total Prior Capital Raised
$1,077,464
VC Backed?
No
Close Date Platform Valuation Total Raised Security Type Status Reg Type
02/13/2025 StartEngine $14,998,357 $72,712 Equity - Common Active RegCF
Create a free account today to gain access to Kingscrowd analytics.
Founders: enhance your startup's credibility on Kingscrowd. Create an account to claim this raise page.
Add to portfolio
ROSE Diagnostics on StartEngine 2024
Platform: StartEngine
Security Type: Equity - Common
Valuation: $14,998,357
Price per Share: $28.84

Follow company

Follow ROSE Diagnostics on StartEngine 2024

Buy ROSE Diagnostics's Deal Report

ROSE Diagnostics Deal Report

Get Kingscrowd's comprehensive report on ROSE Diagnostics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether ROSE Diagnostics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the ROSE Diagnostics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge